



Date: July 13, 2023

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400051

Scrip Code: REMUS

Dear Sir,

Sub: Disclosure under Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2023

Please find enclosed the Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2023. The report has been signed by Mr. Tapan Shah, Company Secretary.

This report is submitted in compliance with Regulation 76 of the SEBI (Depositories and Participants), Regulations, 2018.

This is for your information and records.

Thanking you
Yours faithfully,
For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary
Membership No.: A60090

Encl.: As above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

To,
The Board of Directors,
REMUS PHARMACEUTICALS LIMITED,
1101 to 1103, South Tower, One 42, B/H Ashok Vatika,
Nr. Jayantilal Park BRTS,
Ambli bopal Road, NA Ahmedabad,
Ahmedabad-380054 IN.

RECONCILIATION OF SHARE CAPITAL AUDIT

CIN : U24232GJ2015PLC084536
Authorised Capital : Rs. 2,00,00,000/-

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by **M/s. REMUS PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054 for issuing Certificate, in accordance with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by Securities and Exchange Board of India (SEBI). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I certify that for the quarter ended 30th June, 2023, the details of position of Company's Capital Structure, it's Equity shares position with NSDL, CDSL and Physical, Demat carried out and pending Demat status and other details are as under:

1	For Quarter Ended	30/06/2023	
2	ISIN	INE005T01011	
3	Face Value	Rs. 10/- per Share	
4	Name of the Company	REMUS PHARMACEUTICALS LIMITED	
5	Registered Office Address	1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054 IN.	
6	Correspondence Address	-- Same as above --	
7	Telephone & Fax Nos.	Tel. 079-29999857	
8	Email Address	legal@senorespharma.com; remus@remuspharma.com	
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	The National Stock Exchange of India Ltd. Mumbai – SME emerge market (Symbol- REMUS)	
10	Issued Equity Share Capital	No. of Shares	
		14,73,000	
11	Listed Equity Capital (as per company records)	14,73,000	
12	Held in dematerialised form in NSDL	No. of shares	% of issued Capital
		2,40,575	16.33

13	Held in dematerialised form in CDSL		12,32,425	83.67			
14	Physical		0	0			
15	Total No. of Shares (12+13+14)		14,73,000	100.00			
16	Reason for difference, if any, between (10&11),(11 & 15)		N.A.				
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars	No. of Shares	Applied/ not Applied for Listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimate d to NSDL	In-principle Approval Pending for SE (Specify Names)	
1	3,88,000	Listed as on 29.05.2023	National Stock Exchange-SME emerge (NSE)	Yes	Yes	N.A.	
18	Register of Members is updated (YES/NO) if not, updated up to which date			Yes			
19	Reference of previous quarter with regards to excess dematerialized shares, if any			-- N.A. --			
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter ? If not, reason why ?			-- N.A. --			
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days(in both cases, from the date of Receipt by the Registrar & confirmed by the Registrar is taken), with the reasons for delay :						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	N.A.
Confirmed after 21 days			--	--	--	--	
Pending for more than 21 Days			--	--	--	--	
23	Name, Address, Tel. & Fax No. of the Company Secretary in whole-time practice		Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.& Fax-26430810, 40024320				
24	Appointment of Common Agency for Share Registry Work (Name & Address)		Link Intime India Pvt. Ltd. 5th Floor, 506 to 508, Amarnath Business Centre – I (ABC - I), Nr. St. Xavier's College Corner, Off. C.G.Road, Navrangpura, Ahmedabad-380009 Tel-079-26465179				

25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.)	The Company came out with IPO for 388000 equity shares and allotment was made as on 24/05/2023. Listing was done as on 29/05/2023 with NSE- SME emerge market.
----	---	--

Place: Ahmedabad.
Date: 13/07/2023

Signature:
Name of Company Secretary: **TAPAN SHAH**
C. P. Number: **2839**
UDIN: **F004476E000600126**

Notes:

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. Link In time Private Ltd., as it is not possible to carry out physical verification for any documents.

